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Identification of signaling pathways that maintain and promote adult pancreatic islet functions will accelerate our
understanding of organogenesis and improve strategies for treating diseases like diabetes mellitus. Previous work has
implicated transforming growth factor-b (TGF-b) signaling as an important regulator of pancreatic islet development,
but has not established whether this signaling pathway is required for essential islet functions in the adult pancreas.
Here we describe a conditional system for expressing Smad7, a potent inhibitor of TGF-b signaling, to identify distinct
roles for this pathway in adult and embryonic b cells. Smad7 expression in Pdx1
þ embryonic pancreas cells resulted in
striking embryonic b cell hypoplasia and neonatal lethality. Conditional expression of Smad7 in adult Pdx1
þ cells
reduced detectable b cell expression of MafA, menin, and other factors that regulate b cell function. Reduced
pancreatic insulin content and hypoinsulinemia produced overt diabetes that was fully reversed upon resumption of
islet TGF-b signaling. Thus, our studies reveal that TGF-b signaling is crucial for establishing and maintaining defining
features of mature pancreatic b cells.
Citation: Smart NG, Apelqvist A ˚A, Gu X, Harmon EB, Topper JN, et al. (2006) Conditional expression of Smad7 in pancreatic b cells disrupts TGF-b signaling and induces
reversible diabetes mellitus. PLoS Biol 4(2): e39.
Introduction
A major goal in studies of pancreatic islet development and
diabetes mellitus is the identiﬁcation of signaling pathways
that maintain adult pancreatic islet functions. Pancreatic
islets are comprised of endocrine cells that secrete hormones
including insulin (b cells), glucagon (a cells), somatostatin (d
cells), pancreatic polypeptide (PP cells), and ghrelin (e cells).
Disrupted transforming growth factor-b (TGF-b) signaling
impairs embryonic pancreatic b cell differentiation [1–3],
suggesting essential roles for this pathway in islet develop-
ment. However, redundant TGF-b signaling activities and
pleiotropism from germline mutations producing postnatal
lethality have limited conclusions about the role of this
signaling pathway in adult islets [3–5]. Thus, it remains
unclear if TGF-b signaling disruption may impair islet
function, leading to pathogenesis of diseases like diabetes.
Multiple components of the TGF-b signaling pathways are
expressed in the embryonic and adult pancreas, consistent
with the hypothesis that TGF-b activities regulate pancreas
development and function [3,6–9]. The developing and adult
pancreas expresses multiple TGF-b ligands, like TGF-b1,
activins, and bone morphogenetic proteins (BMPs), which are
known to bind heteromeric receptor complexes comprised of
membrane-associated type I and type II receptor kinases.
Ligand activation of these receptors triggers phosphorylation
of intracellular proteins called receptor-regulated Smads (R-
Smads), which form heteromeric complexes with Smad 4. The
activated Smad complexes translocate to the nucleus, where
they regulate the transcription of target genes. R-Smads 1, 5,
and 8 transduce BMP signaling, while R-Smads 2 and 3 are
thought to mediate TGF-b and activin signaling [10]. The
inhibitory Smads, Smad6 and Smad7, block TGF-b signaling
by blocking R-Smad phosphorylation and may also target
TGF-b receptors for degradation [10–13].
Prior in vivo and in vitro studies have identiﬁed TGF-b
signaling factors necessary for speciﬁc steps of pancreatic
development. b cell differentiation appears to be particularly
sensitive to mutations affecting TGF-b signaling components,
including the activin receptors ActRIIA and ActRIIB, Smad2,
and the ligand growth/differentiation factor 11 (Gdf11 [2–3]).
Recently, we showed that Gdf11 is required for development
of the appropriate number of endocrine precursor cells
expressing the bHLH factor neurogenin3, and for the
differentiation of embryonic b cell precursors into mature
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PLoS BIOLOGYinsulin-producing cells during pancreas development. These
prior studies suggested that TGF-b signaling was required for
b cell differentiation, but the islet cell defects revealed in
these studies were modest and likely reﬂected redundant
TGF-b signaling activities. Mutations in single genes or
compound mutation combinations affecting TGF-b compo-
nents also impaired glucose tolerance in adult animals but
did not produce overt diabetes [2,3]. Based on the mild
physiologic effects following TGF-b signaling disruption in
these and other studies [14,15], it was not possible to conclude
unambiguously that TGF-b signaling was required to main-
tain adult islet cell function. Moreover, it was not known if
the mildly impaired glucose regulation previously observed in
these studies of adult germline mutants provided evidence for
essential TGF-b signaling roles in adult islets, or merely
reﬂected the late, secondary consequences of impaired
embryonic endocrine development.
Several classes of ligands comprise the TGF-b superfamily,
including activins, BMPs, and TGF-b isoforms, and Smad7 is a
potent in vivo inhibitor of signaling by each of these ligand
groups [11,12,16]. We generated transgenic mouse lines that
permit conditional expression of Smad7 in Pdx1-expressing
cells in the embryonic or adult pancreas. Pdx1 is expressed in
all pancreatic progenitor cells and becomes largely restricted
to b cells in islets by the end of embryonic development [17–
19]. Disruption of TGF-b signaling by Smad7 revealed crucial
in vivo roles for the TGF-b pathway in pancreatic b cell
development, and demonstrated that this pathway is essential
for maintaining characteristic features and hallmark func-
tions of adult b cells.
Results
Conditional Expression of Smad7 in Embryonic Pdx1
þ
Cells Disrupts TGF-b Signaling, Foregut Development, and
Endocrine Cell Differentiation
To permit studies of phenotypes following disruption of
pancreatic TGF-b signaling, we generated transgenic mouse
lines that permitted conditional expression of Smad7, a
potent inhibitor of signaling by TGF-b ligands, including
activin, BMPs, and TGF-b isoforms [11,12]. Mice harboring a
transgene encoding Smad7 adjacent to a tetracycline re-
sponse element (TRE) containing a cis-acting heptameric
tetracycline-regulated transactivator (tTA)-binding site and a
minimal promoter were created (hereafter called Smad7 mice;
see Materials and Methods) [20,21]. Smad7 mice were bred
with Pdx1-tTA mice in which the tTa replaces the coding
region of Pdx1, a gene expressed in pancreatic progenitor
cells as well as in adult b cells [17–19,22]. Thus, in Pdx1-tTA
mice, the tTA is expressed in the spatial and temporal pattern
of the endogenous Pdx1 gene. tTA-induced expression of
TRE-Smad7 is repressed upon administration of the drug
doxycycline, a tetracycline analog (Figure 1). Bitransgenic
Pdx1-tTA/Smad7 progeny from this intercross were obtained at
the expected frequency from more than 40 litters.
In 23 bitransgenic embryos raised in the absence of
doxycycline, we observed severe pancreatic malformation
and lethality at postnatal day (P)1 (Figure 1A–1D). We also
observed malformations of the spleen and duodenum, a
pattern of organ defects consistent with the established
expression of Pdx1-tTA in the posterior foregut (unpublished
data) [22]. In the absence of doxycycline in Pdx1-tTA/Smad7
mice, tTA activated expression of Smad7 in Pdx1
þ cells of the
embryonic pancreas (Figure 1E–1G). Bitransgenic embryos
showed a marked decrease in all phosphorylated R-Smads
(Figure S1), which is consistent with the conclusion that
Smad7 expression in our system reduced signaling through
TGF-b pathways.
In Pdx1-tTA/Smad7 embryos, we observed an 85%–90%
reduction of b cells at P1, compared to control littermates
(Figure 1M and 1N; Figure S1). In contrast, the number of
glucagon
þ cells was increased, and these formed anomalous
homogeneous clusters in these mice (Figure 1M–1N; Figure
S1). These defects were observed as early as E15.5 (unpub-
lished data) and were similar to phenotypes we have observed
in mice with germline mutations in speciﬁc TGF-b compo-
Figure 1. Conditional Smad7 Expression in Embryonic Pdx1
þ Cells Leads
to Pancreatic Malformation
(A–D) Whole-mounted abdominal organs from E17.5 embryos with the
indicated genotypes.
(A–C) Views of the pancreas (outlined by dashes) at E17.5 in wild-type
and bitransgenic Pdx1-tTA/Smad7 mice. (C) shows a magnified view of
the pancreatic region marked by the arrow in (B). Adjacent organs
marked in (C): St, stomach; Sp, spleen; Du, duodenum.
(D) Bitransgenic Pdx1-tTA/Smad7 embryos from doxycycline-fed mothers
(þ dox) develop a morphologically normal pancreas.
(E–L) Smad7 (red) or Pdx1 (green) expression detected by immunohis-
tochemistry in the pancreas of E14.5 mice with the indicated genotypes.
(M–O) Immunohistochemical detection of glucagon
þ (red) and insulin
þ
(green) cells at P1 in mice with the indicated genotypes.
(O) Bitransgenic Pdx1-tTA/Smad7 embryos from doxycycline-fed mothers
(þ dox) develop normal-appearing islets. Original magnification is 43for
(A–D), 633 for (E–H), and 203 for (I–O).
DOI: 10.1371/journal.pbio.0040039.g001
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Smad7 Disruption of b Cell Functionsnents [2,3]. We did not observe signiﬁcant changes in the
proportion of cells expressing other islet hormones, includ-
ing pancreatic polypeptide (p ¼ 0.16), somatostatin (p ¼ 0.24),
and ghrelin (p ¼ 0.82). No changes were detected in cell
proliferation or apoptosis in Pdx1-tTA/Smad7 mice at E15.5
and E17.5, as assessed by quantiﬁcation of Ki67 or TdT-
mediated dUTP nick-end labeling (Figure S1 and unpublished
data), suggesting that the observed phenotypes were due to
cell differentiation defects. However, since apoptosis in b
cells can be difﬁcult to discern [23], we cannot strictly rule
out the contribution of programmed cell death to the
phenotypes observed in embryonic Pdx1-tTA/Smad7 mice.
To test whether doxycycline administration could prevent
TRE-Smad7 expression, we fed doxycycline to females
throughout pregnancy and examined Pdx1-tTA/Smad7 prog-
eny. Doxycycline administration to mothers prevented TRE-
Smad7 expression in the embryonic pancreas; only low levels
of endogenous Smad7 expression were detected in bitrans-
genic Pdx1-tTA/Smad7 embryos, similar to wild-type controls
(Figure 1H and 1L). Bitransgenic Pdx1-tTA/Smad7 mice from
doxycycline-fed mothers had normal pancreas (Figure 1D)
and islet development (Figure 1O). When maintained on
doxycycline as adults, Pdx1-tTA/Smad7 animals had normal
glucose regulation (see below). Thus, adult Pdx1-tTA/Smad7
mice provided an opportunity to test the effects of induced
Smad7 expression on b cell functions in vivo, independent of
embryonic defects.
Conditional Disruption of TGF-b Signaling in Adult
Pancreatic Islets
Next, we tested whether our bitransgenic mice could be
used to express Smad7 conditionally in adult pancreatic islets
(Figure 2). In control adults and in bitransgenic Pdx1-tTA/
Smad7 animals continuously exposed to doxycycline from
Figure 2. Doxycycline-Dependent Smad7 Expression and TGF-b Signaling Inhibition in Pdx1-tTA/Smad7 Adult Islets
Data are from tissues of male mice aged 4–5 mo.
(A–C and E–J) Smad7 expression by b cells in wild-type and Pdx1-tTA controls is undetectable while immunohistochemical studies demonstrate Smad7
expression (red) in insulin-expressing b cells (green) of bitransgenic Pdx1-tTA, TRE-Smad7 adults.
(D) RT-PCR studies of purified pancreatic islets confirm increased accumulation of Smad7 mRNA (arrow) in the islets of bitransgenic Pdx1-tTA/Smad7
adults.
(K) In bitransgenic animals induced to overexpress Smad7 then treated with doxycycline (þ dox), Smad7 expression returns to wild-type levels.
(L–N) Immunohistochemical detection of phospho-Smad2 (white).
(L and M) Compared to Pdx1-tTA b cells, accumulation of phospho-Smad2 is decreased in b cells of bitransgenic Pdx1-tTA/Smad7 adults.
(N) phospho-Smad2 expression in b cells of Pdx1-tTA/Smad7 animals treated with doxycycline (þ dox) returns to normal. In (L, N), arrows point to
autofluorescent blood cells. Original magnification of all micrographs is 633.
DOI: 10.1371/journal.pbio.0040039.g002
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Smad7 Disruption of b Cell Functionsconception, islet expression of Smad7 was not detected by
immunohistochemical staining or by RT-PCR (Figure 2A–K,
and unpublished data). The presence of active TGF-b signal-
ing in these islets was indicated by detection of phosphory-
lated Smad2 (phospho-Smad2; Figure 2L and 2N) and
phosphorylated Smad1/5/8 (unpublished data) using polyclo-
nal antisera. Smad7 mRNA in islets and Smad7 protein in b
cells were clearly detected in bitransgenic Pdx1-tTA/Smad7
mice after doxycycline removal (Figure 2D and 2H–2J).
Corresponding with Smad7 expression, we observed reduc-
tion of phospho-Smads from the majority of islet cells (Figure
2M, unpublished data), consistent with the interpretation that
Smad7 misexpression resulted in disrupted TGF-b signal
transduction.
In a subset of bitransgenic Pdx1-tTA/Smad7 mice re-exposed
to doxycycline after a doxycycline-free interval of several
weeks (see Materials and Methods), Smad7 expression in islets
was extinguished (Figure 2K), corresponding with the
reappearance of detectable phospho-Smad2 (Figure 2N).
Thus, b cells in bitransgenic Pdx1-tTA/Smad7 mice remained
competent for endogenous pancreatic signals, and the
reappearance of phospho-Smad2 suggests that one or more
of these signals is a TGF-b ligand. These results demonstrate
our ability to express Smad7 and impair TGF-b signaling
conditionally in adult pancreatic islets.
Smad7 Expression in Adult Islets Induces Overt Diabetes
Within 2–3 wk after doxycycline removal, Smad7 expres-
sion in Pdx1-tTA/Smad7 islets was detected (Figure 2H–J), and
bitransgenic mice (Figure 3) developed signiﬁcant hyper-
glycemia during random feeding (Figure 3A) and showed
impaired glucose tolerance (Figure 3B). Control Pdx1-tTA
littermates, which are heterozygous for a null mutation in
Pdx1, also had impaired glucose tolerance (Figure 3B), but
never developed overt diabetes (Figure 3A), consistent with
prior reports [22,24,25]. Moreover, impaired glucose toler-
ance in Pdx1-tTA mice was signiﬁcantly less severe than that
observed in bitransgenic Pdx1-tTA/Smad7 mice. Thus, Smad7
expression in Pdx1-expressing islets resulted in overt diabetes,
suggesting that Smad7 inhibits processes necessary for
normal b cell function. To test this possibility further, and
to assess the contribution of Pdx1 heterozygosity to diabetes
in these bitransgenic mice, we also studied glucose regulation
in mice simultaneously harboring the RIP-rtTA and TRE-
Smad7 transgenes. The reverse tetracycline transactivator
(rtTA) is expressed from rat insulin promoter (RIP) sequences
in the RIP-rtTA transgene (see Materials and Methods).
Exposure to doxycycline activates the rtTA product, resulting
in Smad7 expression. In bitransgenic RIP-rtTA/Smad7 mice, in
w h i c hb o t hc o p i e so fPdx1 are wild-type, doxycycline
exposure resulted in average blood glucose values .200 mg/
dl during random feeding (Figure 3H). Thus, independent of
Pdx1 heterozygosity, conditional expression of Smad7 in islets
produced overt diabetes.
To determine if islet dysfunction promoted diabetes in
Pdx1-tTA/Smad7 mice, we measured serum and pancreatic
levels of insulin and glucagon, and assessed islet phenotypes.
Serum insulin concentration in Pdx1-tTA/Smad7 mice was
signiﬁcantly reduced relative to littermate controls (Figure
3C). By contrast, we did not detect signiﬁcant differences in
serum glucagon levels (48 6 2 pg/ml in Pdx1-tTA/Smad7 mice
versus 55 6 2 pg/ml in controls; p . 0.05), or numbers of
glucagon
þ cells (1.16% 6 0.32% pancreas area in Pdx1-tTA/
Smad7 mice, n ¼3; 0.74% 6 0.15% pancreas area in Pdx1-tTA
controls, n ¼ 3; p . 0.05). Pdx1
þ/  animals have lower serum
insulin levels because of reductions in key glucose sensing and
insulin secretion pathway components [24,26,27]. In bitrans-
genic animals, these defects were comparable to Pdx1-tTA
controls and could not explain the more severe reduction in
Figure 3. Diabetes and Reduced Pancreatic Insulin Production following
Smad7 Expression in Pancreatic b Cells
Data are presented as the average 6 SEM. Data are from ten litters with
at least four mice per genotype. p-Values and statistical significance in
(A–G) reflects comparison of bitransgenic mice to Pdx1-tTA controls,
unless otherwise indicated.
(A) Random-fed blood glucose levels of male mice with indicated
genotypes. Similar data were obtained for female littermates (unpub-
lished data).
(B) Intraperitoneal glucose challenge of male mice (8–10 wk old) with the
indicated genotypes after a 14-h overnight fast.
(C) Serum insulin from male mice with the indicated genotypes during
random feeding. Mice were 8–10 wk old.
(D) Total pancreatic insulin levels in 10- to 12-wk-old mice with the
indicated genotypes. Insulin levels are expressed as ng/mg pancreas
protein.
(E–G) Reversal of overt diabetes mellitus and impaired insulin levels by
treating bitransgenic Pdx1-tTA/Smad7 mice with doxycycline.
(E) Blood glucose levels during random feeding following exposure of
mice with indicated genotypes and ages (weeks after birth) to
doxycyline.
(F) Intraperitoneal glucose challenge following a 14-h overnight fast in
12- to 14-wk-old mice with the indicated genotypes after 5 wk of
continuous doxycycline exposure.
(G) Serum insulin during random feeding from 12- to 14-wk-old mice
with the indicated genotypes after 5 wk of continuous doxycycline
exposure.
(H) Induction of Smad7 by doxycycline in insulin
þ cells using RIP-rtTA/
Smad7 animals also yields mice with elevated levels of random-fed blood
glucose.
For all panels: * p , 0.05; ** p , 0.01.
DOI: 10.1371/journal.pbio.0040039.g003
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Smad7 Disruption of b Cell Functionsserum insulin or the development of overt diabetes (unpub-
lished data). Therefore, we examined total pancreatic insulin
content in Pdx1-tTA/Smad7 mice following elimination of
dietary doxycycline and found it to be markedly reduced
(Figure 3D). By contrast, wild-type and Pdx1-tTA mice had
normal pancreatic insulin content (Figure 3D). Compared to
Pdx1-tTA controls, hyperglycemia, impaired glucose toler-
ance, and hypoinsulinemia were fully reversed in Pdx1-tTA/
Smad7 mice following re-administration of doxycycline
(Figure 3E–G). Moreover, total pancreatic insulin levels in
Pdx1-tTA/Smad7 mice following resumption of doxycycline
administration were indistinguishable from those in control
littermates (20.8 6 0.8 ng/mg in Pdx1-tTA/Smad7; 17.7 6 5.2
ng/mg in Pdx1-tTA; n ¼ 3–5), and islets in bitransgenic Pdx1-
tTA/Smad7 on doxycycline appeared normal (Figure 4A–4D).
Thus, Smad7-induced disruption of b cell function in Pdx1-
tTA/Smad7 mice was not permanent, and we postulate that
islets in these mice responded to endogenous TGF-b signals
that promptly re-established normal function. Collectively,
our data provide the ﬁrst evidence, to our knowledge, that
disrupted islet TGF-b signaling may impair insulin produc-
tion in adult islets, leading to pathogenesis of overt diabetes.
TRE-Smad7 Induction in Islets Reduces Expression of
Characteristic b Cell Products
We next examined expression of b cell transcription
factors known to govern insulin expression (Figure 4). In
vitro studies have established that the leucine-zipper tran-
scription factor MafA is a direct regulator of insulin
production in b cells [28–31]. In islets of Pdx1-tTA/Smad7
diabetic mice, MafA mRNA assessed by real-time PCR was
reduced (0.72 6 0.11, Pdx1-tTA/Smad7; 1.0 6 0.07, Pdx1-tTA: p
Figure 4. Conditional Smad7 Expression Alters Expression of Factors Important for Maintaining Adult b Cells
Data are from tissues of male mice aged 4–5 mo.
(A–C) Immunofluorescent detection of insulin
þb cells (green) and glucagon
þb cells (red) in wild-type, Pdx1-tTA, and bitransgenic Pdx1-tTA/Smad7 mice.
(C) Islet enlargement was detected in some bitransgenic Pdx1-tTA/Smad7 mice following doxycycline withdrawal.
(D) Islet morphology in paraffin sections appeared normal in bitransgenic Pdx1-tTA/Smad7 animals 5 wk after readministration of doxycycline, as
described in Materials and Methods.
(E–H) Smad7 alters expression of MafA (red) in b cells expressing insulin (green).
(F and G) The number of MafA-expressing b cells in bitransgenic Pdx1-tTA/Smad7 was reduced compared to controls (n ¼ 3).
(E and F) Pdx1-tTA animals also showed a mild decrease in numbers of MafA expressing islet cells relative to wild-type controls.
(H) After diabetic bitransgenic Pdx1-tTA/Smad7 animals were readministered doxycycline (þdox), islet MafA expression appeared normal. Staining was
performed on paraffin sections.
(I–K, M–O) The expression of nuclear p27
kip1 (black, I–K) and Menin (red, M–O) was reduced in adult Pdx1-tTA/Smad7 animals compared to wild-type and
Pdx1-tTA controls (n ¼ 5).
(L) After diabetic bitransgenic Pdx1-tTA/Smad7 animals were readministered doxycycline (þ dox), p27
kip1 expression appeared relatively normal.
(P–R) Nkx6.1 expression (red) was unchanged in Pdx1-tTA/Smad7 animals. Arrows in (H) and (F) mark autofluorescent blood cells. Original magnification
is 203 (A–D, I–L), and 633 (E–H, M–R).
DOI: 10.1371/journal.pbio.0040039.g004
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Smad7 Disruption of b Cell Functions, 0.05; see Materials and Methods), and nuclear MafA in b
cells was substantially decreased in islets from Pdx1-tTA/Smad7
mice (Figure 4E–G; n ¼ 3). Thus, these data provide in vivo
evidence that TGF-b signals may regulate MafA expression in
mature b cells. Reduced MafA expression correlated with
impaired islet and serum insulin levels in Pdx1-tTA/Smad7
mice, consistent with recent evidence that MafA, in con-
junction with other factors, can induce insulin expression in
vivo [32].
In contrast, expression of other b cell transcription factors
known to regulate insulin gene expression, like Nkx6.1, Pdx1,
and NeuroD1, appeared unchanged (Figure 4I–4K, and
unpublished data). In addition, we assessed KLF11 expression
in these mice. KLF11 is a zinc-ﬁnger–containing transcrip-
tional regulator of insulin expression, and recent studies
showed that TGF-b ligand addition to cultured MIN6 b cells
was sufﬁcient to increase KLF11 mRNA levels [33]. Thus,
Smad7 inhibition of TGF-b signaling might be expected to
reduce KLF11 mRNA in Pdx1-tTA/Smad7 mice. Using real-
time RT-PCR, we did not detect a reduction in the level of
KLF11 mRNA expression in islets from Pdx1-tTA/Smad7 mice
compared to Pdx1-tTA controls (3.3 6 0.2 in Pdx1-tTA/Smad7
versus 2.2 6 0.3 in Pdx1-tTA controls). Thus, studies of
Nkx6.1, Pdx1, NeuroD1, and KLF11 indicate that Smad7
expression in Pdx1-tTA/Smad7 islets did not globally impair b
cell functions.
Within 2 wk of doxycycline re-administration to diabetic
Pdx1-tTA/Smad7 mice, Smad7 expression was extinguished
(Figure 2K), islet morphology appeared normal, and MafA
expression was again detectable in b cells (Figure 4D and 4H).
The reversal of these islet defects paralleled the resumption
of normoglycemia, b cell phospho-Smad2 expression (Figure
2N), and increased pancreatic insulin production in these
mice (Figure 3E–G). These results provide strong additional
in vivo evidence that TGF-b signaling maintains the proper-
ties of differentiated islet b cells.
In addition to insulin and MafA, we asked whether Smad7
induction in Pdx1-tTA/Smad7 mice disrupted expression of
other characteristic b cell markers. Menin, the product of the
Men1 gene, and p27
Kip1, the product of Cdkn1b, are expressed
in mature b cells (Figure 4I–4J, 4M, and 4N). b cells proliferate
in islets lacking menin or p27
Kip1, leading to hyperplasia;
thus, these b cell products are required to regulate b cell
proliferation [34–36]. The expression of both menin and
p27
Kip1 was nearly undetectable in islet b cells from all Pdx1-
tTA/Smad7 diabetic mice that were studied (Figure 4K and 4O;
n ¼ 5), suggesting a mechanism for the mild islet hyperplasia
observed in some animals (Figure 4A–4C; 2.5% 6 0.2%
insulin
þ cell area in Pdx1-tTA/Smad7 mice, n ¼ 4; 1.5% 6
0.04% in Pdx1-tTA controls, n ¼ 3; p , 0.05). Although we
observed reduced menin and p27
Kip1 expression in all Pdx1-
tTA/Smad7 diabetic mice that were tested, not all mice had
detectable islet hyperplasia (unpublished data): thus, com-
pensatory b cell growth in Pdx1-tTA/Smad7 diabetic mice was
heterogeneous, and additional studies are needed to eluci-
date the basis for islet growth in this model. Menin is a direct
regulator of p27
Kip1 in b cells [37,38], and exposure of
diabetic Pdx1-tTA/Smad7 mice to doxycycline led to re-
expression of p27
Kip1 (Figure 4L). Thus, Smad7 induction in
Pdx1-tTA/Smad7 mice inhibited expression of factors required
to maintain characteristic b cell functions in adult pancreatic
islets.
Reduced Pancreatic MafA Expression in Gdf11-Deficient
Embryos
To test if loss-of-function mutations that impair TGF-b
signaling can also disrupt terminal b cell differentiation, we
examined mice lacking the TGF-b ligand Gdf11 (Figure 5 and
[39]). In Gdf11
 /  mice, which die on P1, we recently showed
that a subset of Nkx6.1
þcells in the embryonic pancreas failed
to express insulin. This resulted in accumulation of anom-
alous Nkx6.1
þ insulin
  cells, and a greater than 50%
Figure 5. Reduced Expression of MafA by b Cells in Mice Lacking Gdf11
(A and B) Immunohistochemical detection of Nkx6.1 (red) and MafA (green) in wild-type embryos at E17.5.
(C) Merge of (A) and (B).
(D) Coexpression of insulin (green) and MafA (red) in wild-type embryos at E17.5.
(E) Quantification of MafA
þ cells per unit area in Gdf11
þ/þ and Gdf11
 /  embryos.
(F and G) Immunohistochemical detection of Nkx6.1 (red) and MafA (green) in Gdf11
 /  embryos.
(H) Merge of (F) and (G).
(G–I) Reduction of MafA
þ cells in Gdf11
 /  embryos.
(J) Increased number of Nkx6.1
þMafA
 cells in Gdf11
 / mice at E17.5. Asterisks in (E) and (J) indicate p , 0.05. Three to four animals per genotype were
used for quantification. Arrows in (H) indicate autofluorescent blood cells. Original magnification of all images is 633.
DOI: 10.1371/journal.pbio.0040039.g005
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Smad7 Disruption of b Cell Functionsreduction of pancreatic insulin
þ cell mass [3]. However, the
basis for this defect in b cell maturation was not previously
identiﬁed. Coinciding with the onset of insulin expression,
embryonic Nkx6.1
þ cells initiate expression of MafA [30], and
by E17.5 we detected MafA expression in the majority of wild-
type Nkx6.1
þ cells (Figure 5A–C and 5J). By contrast, MafA
expression in Nkx6.1
þ cells was impaired in Gdf11
 /  mice
(Figure 5C, 5H, and 5J), resulting in a more than 50%
reduction of MafA
þ cells in these animals (Figure 5E–5H).
These ﬁndings suggest that impaired MafA expression is one
reason for defective maturation and insulin expression by
differentiating b cells in Gdf11
 /  mice. Thus, similar to the
effect of Smad7 misexpression, loss of Gdf11 reduced MafA
expression in b cells. Collectively, these data suggest that
TGF-b signaling is essential for expression of characteristic b
cell functions in both the embryonic and adult pancreas.
Discussion
These studies reveal a requirement for TGF-b signaling in
maintaining pancreatic islet functions. Using an inducible
system to express Smad7 conditionally in Pdx1
þ cells, we
disrupted TGF-b signaling in adult and nascent embryonic
islets. One principal ﬁnding from this study is that Smad7
expression in adult pancreatic b cells leads to reduced
expression of insulin and nuclear factors like MafA, menin,
and p27
Kip1. Expression of each of these factors in vivo is
normally maintained in mature b cells [28,29,37,38]. Smad7
expression may affect signaling pathways other than those
regulated by TGF-b in speciﬁc in vitro contexts [40], but it has
not been shown that Smad7 activity affects signaling other
than TGF-b pathways in vivo. Moreover, we showed that levels
of phosphorylated R-Smads were reduced in the adult islets
and in embryonic pancreata expressing Smad7. Since TGF-b
signaling is known to increase production of phosphorylated
forms of R-Smad proteins, our data provide good evidence
that TGF-b signaling is impaired by Smad7 induction in islets.
In the developing pancreas, we found that loss of Gdf11, an
endogenous TGF-b ligand required for b cell differentiation
[3], led to impaired expression of MafA in subsets of nascent b
cells. We conclude from these lines of evidence that TGF-b
signaling is required in maturation and maintenance of
pancreatic b cell functions.
Disruption of TGF-b Signaling Impairs Expression of
Hallmark b Cell Factors
Insulin expression is a deﬁning feature of adult b cells; we
showed that Smad7 expression led to severe reduction of
total pancreatic insulin content. To begin to elucidate the
mechanisms underlying insulin deﬁciency in these mice, we
examined expression of known direct transcriptional regu-
lators of insulin expression, and found evidence for reduction
of MafA mRNA and nuclear protein. MafA is a member of the
basic leucine zipper family of transcription factors, and
several prior studies provide evidence that MafA is a direct
regulator of insulin transcription [28–32,41]. Our results raise
the possibility that reduced b cell expression of MafA leads to
impaired insulin expression in bitransgenic Pdx1tTA/Smad7
mice. While we measured a reduction of MafA mRNA in islets
from these animals, the levels of immunostainable MafA
protein in their b cells appeared more severely reduced.
Recent studies have shown that mafA expression in b cells may
be regulated by both transcriptional and post-transcriptional
mechanisms. For example, covalent modiﬁcations can result
in ubiquitin-mediated degradation of MafA protein [42].
Thus, multiple mechanisms may underlie the observed
reduction in MafA following TGF-b signaling disruption in
islets, and further studies are needed to address this point.
Nevertheless, to our knowledge, these data provide the ﬁrst
demonstration of an extracellular signaling pathway that
regulates MafA. Additional studies are needed to identify a
mechanism for MafA reduction in islets after Smad7
misexpression.
Studies of mice with targeted disruptions of MafA suggest
that insulin mRNA expression is reduced but that insulin
protein levels are maintained in MafA-deﬁcient islets [41].
Viewed in the context of prior studies of MafA function [28–
32], these are somewhat paradoxical ﬁndings; if correct, they
suggest that the observed reduction of MafA expression in
Pdx1-tTA/Smad7 mice may not completely account for the
severe decrease in total pancreatic insulin observed in these
mice. If so, we speculate that targets of TGF-b signaling other
than MafA in islets may function to ensure the maintenance
of normal insulin production.
We detected expression of phospho-Smad2 in adult islets,
providing evidence for active TGF-b signaling in islet cells.
These results correlate well with prior results from our lab
and others that demonstrated that TGF-b ligands, receptors,
and R-Smads are expressed in adult islets [7,8]. Smad7
expression led to reduced phospho-Smad2 levels in islets,
consistent with the view that Smad7 disrupted TGF-b signal-
ing in islets. In addition to direct interactions between Smad7
and R-Smads, our studies suggest that Smad7 expression may
also impair TGF-b signaling indirectly through reduced
expression of the nuclear factor menin. Prior studies have
shown that menin directly interacts with nuclear R-Smads,
functioning as a cofactor to control R-Smad DNA binding and
transcriptional activity [43,44]. Menin expression by b cells in
Pdx1tTA/Smad7 mice was clearly reduced; thus, we speculate
that the absence of menin could enhance the inhibitory
effects of Smad7 on downstream target gene expression.
TGF-b Signals Are Necessary for Adult Islet Function
A second principal ﬁnding from this study is that Smad7
expression in b cells leads to conditional diabetes mellitus.
Within 2–3 wk after Smad7 induction, Pdx1-tTA/Smad7 mice
developed overt diabetes, with elevated blood glucose levels,
reduced glucose tolerance, and markedly decreased circulat-
ing insulin levels. Reductions of blood insulin were matched
by corresponding reductions in total pancreatic insulin,
suggesting that insulin production was defective in Pdx1-
tTA/Smad7 mice. These ﬁndings do not rule out the possibility
that other islet b cell functions, including factors regulating
stimulus-secretion coupling, may be disrupted by Smad7
induction and contribute to diabetes pathogenesis in Pdx1-
tTA/Smad7 mice: additional physiologic studies are needed to
test this possibility. Re-exposure to doxycycline and loss of
Smad7 led to rapid reversal of the diabetes in Pdx1-tTA/Smad7
mice, suggesting that defective islets in these animals remain
responsive to endogenous restorative signals. Phospho-
Smad2 expression in islets resumed following cessation of
Smad7 expression, making it likely that one or more
endogenous TGF-b ligand(s) promote this restoration of islet
function.
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b signaling in the adult endocrine pancreas. Previously we
described that adult mice harboring trans-heterozygous null
alleles in the activin receptor IIA and activin receptor IIB
genes have impaired glucose tolerance, reduced b cell mass,
and reduced circulating insulin levels [2]. Likewise, expres-
sion of dominant-negative type II receptor transgenes in b
cells led to hypoinsulinemia and impaired glucose tolerance
[14]. In neither prior study, however, did these genetic
changes progress to overt diabetes, suggesting the possibility
of redundant TGF-b signaling activities to maintain islet
function. Moreover, it remained unclear if the modest
physiologic and morphologic phenotypes observed in this
prior work reﬂected a requirement for TGF-b in main-
tenance of adult islet functions, or instead resulted from
defects in islet differentiation during embryonic pancreas
development [2,3]. Our ability to induce Smad7 expression
speciﬁcally in postnatal Pdx1-tTA/Smad7 mice therefore
provided a unique opportunity to elucidate the roles of
TGF-b signaling in adult islets. Thus, multiple experimental
approaches used in prior studies and the work presented here
provide strong evidence that TGF-b signaling is required to
maintain adult islet functions essential for appropriate in
vivo glucose regulation. Since Smad7 blocks multiple recep-
tor-activated TGF-b signaling pathways, our work has not yet
revealed roles of individual receptor-mediated TGF-b path-
ways in maintaining adult islet functions.
Conditional Disruption of TGF-b Signaling Impairs
Pancreas Development
Smad7 misexpression in the developing pancreas disrupted
morphogenesis and islet differentiation. These observations
ﬁt well with previous studies revealing disrupted pancreas
development in embryos with defects in TGF-b signaling [1–
3]. For example, deﬁciency for the ActRIIB receptor led to
malformation of multiple foregut organs including the
spleen, pancreas, and stomach, and modest islet b cell
hypoplasia [2]. Gdf11, a TGF-b ligand, can bind to ActRIIB
to activate Smad2 and Smad4 [5]. In mice lacking Gdf11 or
Smad2, islet defects similar to those in ActRIIB mutants,
including b cell hypoplasia and impaired insulin synthesis,
were observed [3]. These studies of oligogenic mutant
combinations suggested that TGF-b signaling was required
for b cell differentiation, and raised the possibility that
redundant TGF-b signaling activities regulated b cell fate.
Thus, we postulated that misexpression of a potent TGF-b
signaling inhibitor like Smad7, which is capable of blocking
signaling by TGF-b, activin, BMPs, and corresponding R-
Smads, would generate much more severe b cell hypoplasia
than observed in these prior studies. We observed a severe
reduction of phospho-Smad2/3 and phospho-Smad1/5/8 ex-
pression, and loss of b cells in bitransgenic Pdx1-tTA/Smad7
embryos. Thus, Smad7 expression was sufﬁcient to disrupt
TGF-b signaling signiﬁcantly, resulting in a nearly complete
absence of insulin
þ b cells. We speculate that this method for
conditional Smad7 expression may be useful for elucidating
TGF-b roles in other organs and tissues.
Near-complete b cell loss precluded detailed analysis of the
fate of b cells in bitransgenic Pdx1-tTA/Smad7 embryos. To
study the basis for reduction of insulin
þ cells in mice with
disrupted TGF-b signaling, we therefore analyzed Gdf11-
deﬁcient embryos, which displayed defects in pancreatic islet
cell differentiation similar (although qualitatively less severe)
to those in Pdx1-tTA/Smad7 mice. In Gdf11
 /  animals, we
observed the failure of Nkx6.1
þ cells to express MafA, a step
known to presage the onset of insulin expression by b cell
progenitors during islet formation [30] Thus, TGF-b signaling
appears to be essential for b cell maturation in pancreas
development.
In conclusion, our data support the hypothesis that TGF-b
signaling is required to establish and maintain hallmark
functions of mature b cells in pancreatic islets. Reversal of
diabetes and resumption of normal b cell function in our
studies of conditional TGF-b signaling disruption suggests
that dysfunctional islets in diabetic animals may remain
responsive to restorative signals. Identiﬁcation of endoge-
nous TGF-b ligands, signal transduction components, and
targets of TGF-b signaling in islets therefore merits further
study. Dissection of pathways that establish and maintain
deﬁning properties of b cells will be useful for creating cell-
based strategies to treat pancreatic endocrine disorders like
diabetes mellitus.
Materials and Methods
Generation, breeding, and genotyping of mice. Plasmid TRE-
Smad7 was constructed by inserting a 3.0-kb EcoRI-BamHI PCR clone
of human Smad7 (hSmad7) [21] downstream of TRE, which consists of
seven copies of the tet operator and a minimal CMV promoter
(Clontech Laboratories, Palo Alto, California, United States). After
gel puriﬁcation, the TRE-Smad7 DNA fragment was microinjected
into the pronuclei of fertilized mouse eggs in the Stanford University
Transgenic Core Facility. The injected embryos were cultured in vitro
to the two-cell stage and transferred into the oviducts of 0.5-d
pseudopregnant female mice. Mice were genotyped for the presence
of the transgenes by PCR using the following forward (F) and reverse
(R) primers: F ¼ CCCAATGACCACGAGTTTATGC; and R ¼
CTGACAAGTGAAATGATGACCGC. The PCR reaction for TRE-
Smad7 was performed by denaturation at 95 8C for 10 min and 35
cycles of ampliﬁcation (95 8C for 45 s, 62 8C for 60 s, and 72 8C for 90
s), followed by a 10-min extension period at 72 8C. From 20
independent lines, three TRE-Smad7 founders transmitted the
integrated transgene as assessed by PCR and Southern analyses, and
had no detectable ectopic Smad7 expression. One of these TRE-
Smad7 mouse lines, line C, was used in these studies. Doxycycline (1 g/
l) was administrated orally in the drinking water and replaced three
times per week. Targeted disruption and genotyping of Gdf11 [3,39]
and the construction and genotyping of Pdx1-tTA mouse strains have
already been described [22]. Genomic DNA was prepared from
embryonic heads or yolk sacs and adult tails as previously described
[45]. RIP-rtTA animals were obtained from the Joslin Diabetes Center
(gift from Drs. D. Mathis and C. Benoiste, Boston, Massachusetts,
United States). Genotyping protocols and primers were the same as
for the Pdx1-tTA animals. Pdx1-tTA animals were maintained on a
C57BL/6J background. Gdf11
þ/  and RIP-rtTA animals were main-
tained on a mixed 129/Sv-C57BL/6J hybrid genetic background.
Morphometric and histologic methods. Point-counting morphom-
etry, hormone-positive area, and adult islet area were performed
using standard morphometric techniques [2,3]. The entire pancreas
of both embryonic and adult mice was serially sectioned, and 11–25
independent sections per pancreas were stained and counted. To
obtain representative results, all quantiﬁcation of immunostaining
was performed by counting numbers of positive-stained cells and
dividing by the area of total pancreatic tissue. Data were collected
from at least three animals per genotype. All data represent the
average of the indicated number of animals 6 the standard error of
the mean (SEM). Two-tailed t tests were conducted to determine
statistical signiﬁcance. Unless otherwise noted, all immunoﬂuores-
cence presented here was performed on cryogenic sections. Cryo-
genic sections were prepared as follows: following brief ﬁxation in
4% paraformaldehyde, tissue was soaked with 30% sucrose overnight,
embedded in O.C.T. compound (Tissue-Tek; Electron Microscopy
Sciences, Hatﬁeld, Pennsylvania, United States) and frozen. Micro-
tomy of parafﬁn and frozen tissues resulted in sections 7–10 lm thick.
Immunohistochemistry, immunoﬂuorescence, and localization of
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previously described [2]. Immunoﬂuorescent pictures were captured
using confocal microscopy. Antigen retrieval (Vector Laboratories,
Burlingame, California, United States) was used on all parafﬁn and
cryogenic sections stained with antisera for nuclear factors except for
menin. The primary antisera used were: guinea pig anti-glucagon
(1:100; Linco, St. Charles, Missouri, United States), mouse anti-
glucagon (1:500; Sigma-Aldrich, St Louis, Missouri, United States),
guinea pig anti-insulin (1:100; Linco, or 1:250; Abcam, Cambridge,
United Kingdom), mouse anti-Ki67 (1:200; BD Pharmingen, San
Diego, California, United States), rabbit anti-MafA (1:500; Bethyl
Laboratories, Montgomery, Texas, United States) rabbit anti-Menin
(1:200; Santa Cruz Biotechnologies, Santa Cruz, California, United
States), guinea pig anti-Nkx6.1 (1:1000; M. Sander, University of
California at Irvine, Irvine, California, United States), rabbit anti-
Pdx1 (1:200; C. Wright, Vanderbilt University, Nashville, Tennessee,
United States, or 1:500; Chemicon, Temecula, California, United
States), rabbit anti-phospho Smad1/5/8, phospho-Smad2 and phos-
pho-Smad2/3 (1:50; Chemicon), mouse anti-p27
Kip1 (1:50; Pharmin-
gen), goat anti-Smad7 (1:100; Santa Cruz Biotechnologies). Secondary
antibodies (Jackson ImmunoResearch, West Grove, Pennsylvania,
United States) for immunoﬂuorescent or peroxidase detection of
primary antibodies were respective animal Ig conjuguated to Cy3
(1:400), FITC (1:200), or biotin (1:200). MafA was detected using a
biotinylated secondary antibody followed by streptavidin-Cy3 or
FITC (1:1000 or 1:200; Jackson ImmunoResearch). Tissues for anti-
menin immunostaining were treated with 0.1% pepsin in 0.1% HCl
for 5 min to expose the antigen. Immunoperoxidase detection
for insulin and p27
Kip1 antibodies was performed using
Vectastain Elite ABC and DAB kits (Vector Laboratories).
Islet isolation and PCR methods. Islets were isolated and RNA
prepared using previously described methods [46]. Genomic DNA was
removed using 1 ll of RNase-free DNase-I (Boehringer, Ingelheim,
Germany) per 1.5 lg RNA. cDNAs were synthesized as previously
described [2]. RT-PCR for human Smad7 transcript was performed
on standardized amounts of cDNA using the following forward (F)
and reverse (R) primers: F¼GCTTGCTGGCCTAATAGCAG; and R¼
GCAGGACACCCTGATAGGAA. These primers are predicted to give
a 697-bp band and were designed to span the ﬁrst intron of hSmad7.
The RT-PCR band of this size was gel-isolated with a commercial kit
(Qiagen, Valencia, California, United States) and sequenced (Seque-
tech, Mountain View, California, United States) to conﬁrm the
speciﬁcity of the PCR. Real-time RT-PCR was performed using a 7300
Real Time PCR System from Applied Biosystems (ABI, Foster City,
California, United States) on cDNA made from islets isolated from
three animals per genotype to ensure adequate RNA isolation. Real-
time RT-PCR on islets was performed in triplicate for each condition
and results presented as the mean 6 SEM. MafA and KLF11 real-time
RT-PCR were quantiﬁed relative to a b-actin internal control.
Labeled primers were from ABI.
Animal care and metabolic studies. Animals were maintained on a
standard light/dark cycle and handled in accordance with Stanford
University Animal Care and Use guidelines. Smad7 expression in
Pdx1-tTA/Smad7 embryos was inhibited by providing pregnant
females doxycycline (1 g/l) in their drinking water. To permit Smad7
expression during embryogenesis, pregnant females were maintained
without doxycycline throughout pregnancy, and litters were collected
at speciﬁed times. To induce Smad7 in Pdx1-tTA/Smad7 adults,
animals born to doxycycline-fed mothers were maintained on
doxycycline until 3 wk of age. Animals were then taken off
doxycycline and subjected to physiologic testing (see text). In some
Pdx1-tTA/Smad7 mice and age-matched littermates taken off
doxycycline at 3–5 wk of age, doxycycline administration (1 g/l) was
resumed at 7–9 wk of age. Animals were subjected to physiologic tests
and then sacriﬁced at 5 mo of age for total pancreatic insulin analysis.
All data collected were from at least three animals per genotype. In
contrast to the tTA gene product expressed from the Pdx1 locus,
which is inhibited by doxycycline, the rtTA protein expressed from
RIP cis-regulatory elements in the RIP-rtTA transgene is activated by
doxycycline. Thus, to induce Smad7 expression in RIP-rtTA/Smad7
animals, animals were given doxycycline (1 g/l) in their drinking water
at 3 wk of age and maintained on doxycycline for 7 wk. Blood glucose
concentration and glucose tolerance tests were measured weekly, as
described [2,47]. Serum insulin concentrations were obtained either
from mouse tail bleeds or from the hearts of anesthetized mice
immediately prior to sacriﬁce [47]. Pancreatic insulin content was
measured after the pancreas was homogenized in 70% acid-ethanol
[24]. To allow comparison of pancreatic insulin content in different
groups of mice, insulin levels were normalized to pancreatic protein
content or weight. Both serum insulin and total pancreatic insulin
concentrations were determined using the Mercodia Ultrasensitive
Mouse Insulin ELISA kit (Alpco Diagnostics, Windham, New
Hampshire, United States). Glucagon concentration was determined
by radioimmunoassay (Linco).
Supporting Information
Figure S1. Smad7 Expression Impairs TGF-b Signaling and Disrupts
Embryonic Pancreas Development
(A–D) Immunostaining with antiserum that detects phosphorylated
Smad1, Smad5, and Smad8 (‘‘p-Smad1/5/8’’ [D–E]) or phosphorylated
Smad2 and Smad3 (‘‘p-Smad2/3’’ [F–G]) in pancreatic epithelia at P1
in mice with the indicated genotype. Compared to wild-type controls,
expression of p-Smad1/5/8 and p-Smad2/3 is clearly reduced in
bitransgenic Pdx1-tTA/Smad7 mice.
(E–H) Immunostaining with reagents to detect apoptotic TdT-
mediated dUTP nick-end labeling
þnuclei (E–F, arrows) or replicating
Ki67
þ cells (G–H, white nuclei) in pancreatic epithelia at E15.5 is
indistinguishable in wild-type and bitransgenic Pdx1-tTA/Smad7 mice.
Original magniﬁcation is 203 for all micrographs.
(I) Defects in numbers of insulin
þ or glucagon
þ cells was revealed by
immunostaining and morphometry. % cells/area was measured as
described in Materials and Methods on three animals per genotype.
*p , 0.05.
Found at DOI: 10.1371/journal.pbio.0040039.sg001 (1.5 MB JPG).
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